Metastatic Gastric Adenocarcinoma
Conditions
Keywords
Apatinib, Irinotecan, Second-line, Metastatic Gastric Adenocarcinoma
Brief summary
This is a prospective, multicenter, single-group clinical study of Apatinib Plus Irinotecan as second-line treatment in locally advanced or metastatic gastric or gastroesophageal junctional adenocarcinoma.
Detailed description
This is a prospective, multicenter, single-group clinical study of Apatinib Plus Irinotecan as second-line treatment in locally advanced or metastatic gastric or gastroesophageal junctional adenocarcinoma. Interventions: Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day). Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities. Primary Outcome Measure: PFS. Secondary Outcome Measures: OS, ORR, DCR.
Interventions
DRUGApatinib
Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
DRUGIrinotecan
Irinotecan was used as second line treatment with AGC
Sponsors
The First Affiliated Hospital of Dalian Medical University
The Second Affiliated Hospital of Dalian Medical University
Liaoning Cancer Hospital & Institute
Shengjing Hospital
General Hospital of Shenyang Military Region
The People's Hospital of Liaoning Province
Anshan Tumor Hospital
Benxi Cental Hospital
Liaoyang Central Hospital
The Affiliated Tumor Hospital of Harbin Medical University
The Second Affiliated Hospital of Harbin Medical University
Panjin Central Hospital
Jilin University Sino-Japanese Friendship Hospital
The First Hospital of Jilin University
Liaoyang Petrochemical General Hospital
China Medical University, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Age：18-70，female or male. 2. Pathologically diagnosed local advanced or metastatic stomach or gastroesophageal junction with adenocarcinoma, at least one measurable objective tumor lesion by spiral CT examination（according to RECIST 1.1）. 3. First-line application of fluorouracil-based chemotherapy failed (treatment failure definition: toxic side effects can not tolerate the progress of the disease during treatment or recurrence after treatment); Note:(1) Time of first-line treatment for subjects with advanced tumour must more than 1 cycles;(2) Adjuvant/neoadjuvant therapy was allowed; adjuvant/neoadjuvant therapy will be considered as a first-line treatment if disease recurrence during treatment or after less than 24 weeks. 4. UGT1A1\*28(6/6) and \*6(G/G) ,or UGT1A1\*28(6/6) and \*6(G/A),or UGT1A1\*28(6/7) and \*6(G/G). 5. ECOG performance status 0-1. 6. satisfactory main organ function，laboratory test must meet the following criteria: (1) blood routine examination standards to meet: A. HB≥90g/L; B. ANC≥1.5×109/L; C. PLT≥90×109/L; (2) biochemical tests to meet the following criteria: A. Total bilirubin≤1.5 times the upper limit of normal (ULN) B. ALT and AST≤2.5ULN; C. Serum Cr≤1ULN, endogenous creatinine clearance\> 60ml/min (Cockcroft-Gault formula) 7. The international normalized ratio (INR) ≤ 1.5 and some prothrombin time (PPT or APTT) ≤ 1.5ULN within 7 days before participating. 8. Expected survival≥3 months; 9. Signed informed consent (ICF) before admission; 10. Women of childbearing age must undergo a pregnancy test (serum or urine) within 7 days prior to enrollment and have a negative result and are willing to use appropriate methods for contraception at 8 weeks after the trial and at the end of the last test. For men, contraception should be used for surgical sterilization, or agreed to use the appropriate method 8 weeks after the trial and the last given test drug.
Exclusion criteria
1. Hypersensitivity to apatinib, irinotecan or excipients. 2. More than one chemotherapy regimen was treated after progression of gastric cancer (except for adjuvant/neoadjuvant chemotherapy with more than 24 weeks of clearance). 3. Prior exposure to irinotecan. 4. Prior exposure to irinotecan VEGFR inhibitors, such as apotinib, sorafenib, sunitinib. 5. Another primary tumor in patients, except for: systematically treatment non-melanoma skin cancer, effectively treatment cervical carcinoma in situ, or other effectively treatment tumors wtih no recurrence for more than 5 years. 6. Anti neoplastic cytotoxic drugs, biological drugs (such as monoclonal antibodies), immunotherapy (such as interleukin 2 or interferon), or other research drugs have been use within 4 weeks before participating. 7. Uncontrolled hypertention with systolic blood pressure\> 140 mmHg or diastolic blood pressure\> 90 mmHg, grade I or more coronary heart disease, grade I arrhythmia (including QTc interval: male\> 450 ms, female\> 470 ms) and grade I cardiac insufficiency. 8. Urine routine urinary protein ≥ ++, or 24 hours urine protein ≥ 1g. 9. Any toxicity more than 1 grade(according to CTCAE) caused by previous treatment, except hair loss. 10. Occasional artery/venous thrombosis events, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism occurred within 12 months before participation; 11. Intestinal obstruction occurred 4 weeks before participation. 12. Patients who underwent major surgery 4 weeks prior to initiation of treatment. The patient must be cured from any major surgery. 13. Patients who are considered to have a greater risk of medical care due to a serious, uncontrollable disease, non-metastatic systemic disease or active, uncontrollable infection. Some examples include, but not exclusively, uncontrolled ventricular arrhythmias, recent (3 months) myocardial infarction, uncontrollable epilepsy seizures, unstable spinal cord compression, superior vena cava syndrome, HRCT tips Bilateral interstitial lung disease or any mental illness that may obstruct informed consent. 14. Immunocompromised patients, for example, serological tests suggest that human immunodeficiency virus (HIV) is positive. 15. Pregnant or lactating women. 16. Have a variety of factors that affect oral medication (such as unable to swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.). 17. Patients with clear gastrointestinal bleeding tendencies. Including the following: there is black stool, hematemesis history in 2 months can not be grouped; For patient with fecal occult blood (+) and the primary tumor of the stomach tumor not surgical resected, if the center of the main investigators believe that there is possible occurrence of gastrointestinal bleeding,the patient can not be grouped. 18. Ascites or pleural effusion requiring clinical treatment of persistent. 19. A history or evidence of hereditary hemorrhagic physical or coagulopathy that increases the risk of bleeding. 20. With central nervous system metastasis with symptoms. 21. With Gilbert syndrome. 22. Participated in other drug clinical trials in four weeks. 23. Researchers believe that they are not suitable for inclusion. 24. Patients who had bone metastases and had undergone palliative radiotherapy (radiotherapy\> 5% bone marrow area) within 4 weeks prior to the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival [PFS] | 5-6 months | Progression Free Survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival [OS] | 12-15 months | Overall Survival |
| Objective Response Rate [ORR] | 12-15 months | Objective Response Rate |
| Disease Control Rate [DCR] | 12-15 months | Disease Control Rate |
Other
| Measure | Time frame | Description |
|---|---|---|
| Performance Status [WHO-ECOG] | 12-15 months | Performance Status |
| Quality of Life [WHO-QOL] | 12-15 months | Quality of Life |
| Incidence and Degree of Treatment-Emergent Adverse Events [Safety and Tolerability] | 12-15 months | Incidence and Degree of Treatment-Emergent Adverse Events |
Countries
China
Contacts
Primary ContactYunPeng Liu, PhD
Backup ContactXiujuan Qu, PhD
Outcome results
None listed